Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
OPXA's Cash-to-Debt is ranked higher than
94% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OPXA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OPXA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 15.6 Max: No Debt
Current: No Debt
Equity-to-Asset 0.60
OPXA's Equity-to-Asset is ranked lower than
55% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OPXA: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
OPXA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1246  Med: 0.34 Max: 0.78
Current: 0.6
-1246
0.78
Interest Coverage No Debt
OPXA's Interest Coverage is ranked higher than
92% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPXA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPXA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -32.84
Beneish M-Score: 49.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -299.21
OPXA's Operating Margin % is ranked lower than
63% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. OPXA: -299.21 )
Ranked among companies with meaningful Operating Margin % only.
OPXA' s Operating Margin % Range Over the Past 10 Years
Min: -1184.59  Med: -941.04 Max: -299.21
Current: -299.21
-1184.59
-299.21
Net Margin % -297.83
OPXA's Net Margin % is ranked lower than
63% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. OPXA: -297.83 )
Ranked among companies with meaningful Net Margin % only.
OPXA' s Net Margin % Range Over the Past 10 Years
Min: -1314.6  Med: -1183.33 Max: -297.83
Current: -297.83
-1314.6
-297.83
ROE % -111.38
OPXA's ROE % is ranked lower than
80% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. OPXA: -111.38 )
Ranked among companies with meaningful ROE % only.
OPXA' s ROE % Range Over the Past 10 Years
Min: -654.63  Med: -124.2 Max: -32.36
Current: -111.38
-654.63
-32.36
ROA % -72.40
OPXA's ROA % is ranked lower than
77% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. OPXA: -72.40 )
Ranked among companies with meaningful ROA % only.
OPXA' s ROA % Range Over the Past 10 Years
Min: -345.19  Med: -91.83 Max: -24.27
Current: -72.4
-345.19
-24.27
ROC (Joel Greenblatt) % -1131.09
OPXA's ROC (Joel Greenblatt) % is ranked lower than
62% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. OPXA: -1131.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OPXA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1465.29  Med: -994.37 Max: -410.49
Current: -1131.09
-1465.29
-410.49
3-Year EBITDA Growth Rate -41.70
OPXA's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. OPXA: -41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OPXA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.45 Max: 43.2
Current: -41.7
0
43.2
3-Year EPS without NRI Growth Rate -42.70
OPXA's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. OPXA: -42.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OPXA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.4 Max: 51.8
Current: -42.7
0
51.8
GuruFocus has detected 2 Warning Signs with Opexa Therapeutics Inc $OPXA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OPXA's 10-Y Financials

Financials (Next Earnings Date: 2017-06-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OPXA Guru Trades in Q1 2016

Jim Simons 148,189 sh (+9.54%)
» More
Q2 2016

OPXA Guru Trades in Q2 2016

Jim Simons 169,089 sh (+14.10%)
» More
Q3 2016

OPXA Guru Trades in Q3 2016

Jim Simons 198,689 sh (+17.51%)
» More
Q4 2016

OPXA Guru Trades in Q4 2016

Jim Simons 11,305 sh (-94.31%)
» More
» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:BSTG, OTCPK:GRSO, OTCPK:MYMX, OTCPK:ISCO, OTCPK:WSSRF, OTCPK:ENUM, OTCPK:ARNI, OTCPK:MDFZF, NAS:XTLB, OTCPK:NMUS, OTCPK:AMAR, OTCPK:SVON, NAS:CBIO, OTCPK:SARSF, OTCBB:RGBP, OTCPK:ENDV, OTCPK:CDXI, NAS:CERC, AMEX:APHB, OTCPK:STLT » details
Traded in other countries:P6NP.Germany,
Opexa Therapeutics Inc is engaged in developing personalized immunotherapy to treat illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica. These therapies are based on proprietary T-cell technology.

Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.

Ratios

vs
industry
vs
history
PB Ratio 1.33
OPXA's PB Ratio is ranked higher than
83% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. OPXA: 1.33 )
Ranked among companies with meaningful PB Ratio only.
OPXA' s PB Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.57 Max: 11.14
Current: 1.33
0.96
11.14
PS Ratio 1.87
OPXA's PS Ratio is ranked higher than
88% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. OPXA: 1.87 )
Ranked among companies with meaningful PS Ratio only.
OPXA' s PS Ratio Range Over the Past 10 Years
Min: 1.33  Med: 12.56 Max: 77.02
Current: 1.87
1.33
77.02
Current Ratio 2.12
OPXA's Current Ratio is ranked lower than
73% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OPXA: 2.12 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.14 Max: 13.24
Current: 2.12
0.01
13.24
Quick Ratio 2.12
OPXA's Quick Ratio is ranked lower than
69% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OPXA: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.14 Max: 13.24
Current: 2.12
0.01
13.24
Days Sales Outstanding 7.29
OPXA's Days Sales Outstanding is ranked higher than
89% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. OPXA: 7.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPXA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.29
Current: 7.29
0
7.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -99.40
OPXA's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. OPXA: -99.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OPXA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -393.2  Med: -70.3 Max: 0
Current: -99.4
-393.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.93
OPXA's Price-to-Net-Cash is ranked higher than
84% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. OPXA: 1.93 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OPXA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.08  Med: 6.51 Max: 217.12
Current: 1.93
1.08
217.12
Price-to-Net-Current-Asset-Value 1.80
OPXA's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. OPXA: 1.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OPXA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.99  Med: 5.24 Max: 122.88
Current: 1.8
0.99
122.88
Price-to-Tangible-Book 1.33
OPXA's Price-to-Tangible-Book is ranked higher than
87% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. OPXA: 1.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OPXA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.62  Med: 3.8 Max: 119.82
Current: 1.33
0.62
119.82
Price-to-Median-PS-Value 0.15
OPXA's Price-to-Median-PS-Value is ranked higher than
95% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. OPXA: 0.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OPXA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1.1 Max: 6.13
Current: 0.15
0.15
6.13
Earnings Yield (Greenblatt) % 15059.54
OPXA's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. OPXA: 15059.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OPXA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -49607.86  Med: 1275.3 Max: 15059.54
Current: 15059.54
-49607.86
15059.54

More Statistics

Revenue (TTM) (Mil) $2.90
EPS (TTM) $ -1.19
Beta1.94
Short Percentage of Float10.05%
52-Week Range $0.50 - 4.93
Shares Outstanding (Mil)7.14

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 27 12
EPS ($) 2.19 -1.89 -1.73 -0.09
EPS without NRI ($) 2.19 -1.89 -1.73 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 01 2017
Opexa Facility Becomes Foundation for Contract Manufacturing and Development Organization for... Feb 01 2017
These 5 Stocks Under $10 Could Explode Higher Soon Jan 12 2017
ETFs with exposure to Opexa Therapeutics, Inc. : December 23, 2016 Dec 23 2016
ETFs with exposure to Opexa Therapeutics, Inc. : December 12, 2016 Dec 12 2016
ETFs with exposure to Opexa Therapeutics, Inc. : December 1, 2016 Dec 01 2016
OPEXA THERAPEUTICS, INC. Financials Nov 22 2016
ETFs with exposure to Opexa Therapeutics, Inc. : November 18, 2016 Nov 18 2016
Opexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Opexa Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 14 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Nov 14 2016
OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2016
Opexa Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 14 2016
Biotech Movers on Thursday: Cempra Inc (CEMP) And Opexa Therapeutics Inc (OPXA) Nov 03 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Nov 02 2016
Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of... Nov 02 2016
Opexa Announces Reduction in Workforce in Light of Top-Line Results from Phase 2b Abili-T Trial of... Nov 02 2016
6 Companies That Destroyed Shareholders Last Week Oct 29 2016
GNC Deal Could Be In Jeopardy, Genocea Taming Herpes, Opexa Not Taming MS, Plus The Latest on... Oct 28 2016
Is This the Beginning of the End of Opexa? Oct 28 2016
Opexa Therapeutics Announces Phase 2b Abili-T Trial of Tcelna® (imilecleucel-T) in Secondary... Oct 28 2016
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 28 2016
Opexa Therapeutics Announces Phase 2b Abili-T Trial of Tcelna(R) (imilecleucel-T) in Secondary... Oct 28 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : October 17, 2016 Oct 17 2016
ETF’s with exposure to Opexa Therapeutics, Inc. : October 5, 2016 Oct 05 2016
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 11 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter... Aug 09 2016
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update May 12 2016
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016... May 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)